Investigator's choice of treatment

DRUG2 trials

Sponsors

Boehringer Ingelheim, AstraZeneca

Conditions

Breast NeoplasmsChronic Lymphocytic LeukaemiaModerate to Severe Cardiac ImpairmentNeoplasm Metastasis

Phase 2

Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

CompletedNCT01441596

Boehringer IngelheimBreast Neoplasms, Neoplasm Metastasis

Start: 2011-10-31End: 2014-08-31Updated: 2015-09-07

Phase 4

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

RecruitingNCT06651970

AstraZenecaChronic Lymphocytic Leukaemia, Moderate to Severe Cardiac Impairment

Start: 2025-02-04End: 2030-08-16Target: 60Updated: 2026-08-14

Related Papers

Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.

2015-11-1799 citations